双歧杆菌三联活菌肠溶胶囊对非酒精性脂肪肝患者肝功能及炎症因子的影响

Influence of Bifid Triple Viable Enteric-coated Capsules on Liver Function and Inflammatory Factor in Patients with Non-alcoholic Steatohepatitis

目的:探讨双歧杆菌三联活菌肠溶胶囊对非酒精性脂肪肝患者肝功能及炎症因子的影响。方法:非酒精性脂肪肝患者70例随机分为对照组和观察组。两组患者均予常规内科保肝治疗,观察组在此基础上加用双歧杆菌三联活菌肠溶胶囊420 mg,po,tid,连用4周。观察并比较两组患者治疗前后肝功能指标和血清超敏C反应蛋白(hs-CRP)、白细胞介素(IL)-6和IL-8水平的变化及安全性。结果:治疗4周后,两组患者ALT、GGT、血清hs-CRP、IL-6和IL-8水平均较前明显下降(P<0.05或0.01),且观察组下降值明显大于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌三联活菌肠溶胶囊辅助治疗非酒精性脂肪肝能明显降低血清hs-CRP、IL-6和IL-8水平,抑制肝内炎症及免疫损伤,改善肝功能,且安全性较好。

Objective： To discuss the influence of bifid triple viable enteric-coated capsules on liver function and inflammatory factor in the patients with non-alcoholic steatohepatitis （NASH）. Methods： Totally 70 cases of patients with NASH were selected and divided into the control group and the observation group at random. The patients in the two groups were all given routine hepatoprotective therapy. The patients in the observation group were additionally given 420mg bifid triple viable enteric-coated capsules, three times a day for 4 weeks. Except for bifid triple viable enteric-coated capsules, the patients in the control group were given the： same medical treatment as that in the observation group. The changes of liver function index, serum high sensitivity C reaction protein （hs-CRP） , IL-6 and IL-8 levels in the two groups before and after the medical treatment were observed and the security was compared. Results： After the 4-week medical treatment, ALT, GGT, serum hs-CRP, IL-6 and IL-8 levels in the two groups were obviously declined than those before the treatment （P 〈0.05 or P 〈0. O1 ） , and the declining rate in the observation group was much higher than that in the control group （ P 〈 O. 05 ）. Totally 6 and 4 cases of adverse drug reaction （ADR） respectively appeared in the observation group and the control group during the medical treatment with mild symptom, and the difference was without statistical significance （ P 〉 0.05 ）. Conclusion ： Bifid triple viable enter/c-coated capsules in the treatment of NASH can obviously reduce the serum hs-CRP, IL-6 and IL- 8 levels, inhibit the intrahepatic inflammation and immunologic injury, and improve the liver function index with high security.